Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast
The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.